Here Are the Early Results From the First US CRISPR Trial for Cancer – Philadelphia magazine
Posted: November 11, 2019 at 3:43 am
News
This year, researchers from the University of Pennsylvania launched the first-ever clinical trial to genetically edit the immune cells of cancer patients using the technology.
Penn Perelman Center for Advanced Medicine | Courtesy photo
Researchers from the Abramson Cancer Center at the University of Pennsylvania are the first in the United States to attempt to genetically edit a cancer patients immune cells in the lab using CRISPR-Cas9 technology. Penn launched the first-ever U.S. clinical trial for this research earlier this year with support from the Parker Institute for Cancer Immunotherapy(PICI) andTmunity Therapeutics. On Wednesday, researchers confirmed they have successfully infused three participants in the trial thus far two with multiple myeloma and one with sarcoma and have observed the edited cells expand and bind to their tumor target with no serious side effects.
This trial is primarily concerned with three questions: Can we edit T cells in this specific way? Are the resulting T cells functional? And, are these cells safe to infuse into a patient? This early data suggests that the answer to all three questions may be yes, said Edward Stadtmauer, the studys principal investigator and the section chief of hematologic malignancies at Penn.
Its still too early, however, to answer the more pressing question the trial has posed: Can these genetically modified cells destroy cancer cells? But researchers believe the feasibility and safety theyve demonstrated so far provides optimism that the approach may be applicable across multiple areas of gene therapy research.
These early findings are the first step as we determine if this new breakthrough technology can help rewrite how we treat patients with cancer and perhaps other deadly diseases, said Sean Parker, the billionaire entrepreneur and founder and chairman of PICI. CRISPR editing could be the next generation of T-cell therapy, and we are proud to be a part of the first human trial in the United States.
It has taken Penn more than two years to get the appropriate institutional and federal regulatory approvals, and to recruit optimal participants for the trial. Patients had to be screened ahead of time to make sure their tumors were a match for the approach. Participants who met the requirements received other therapy as needed while they waited for their cells to be manufactured. Once that process was complete, all three received the gene-edited cells in a single infusion after a short course of chemotherapy.
Analysis of blood samples revealed that the CRISPR-edited T cells expanded and survived in all three participants. While none of the patients cancer cells have yet responded to the therapy, researchers say there were no treatment-related serious adverse events.
CRISPR has been more popularly known for its ethically questionable potential to alter human DNA, but the studys senior author and immunotherapy pioneer Carl June says his team is squarely focused on moving the field of gene therapy forward.
Our use of CRISPR editing is geared toward improving the effectiveness of gene therapies, not editing a patients DNA, June said. We leaned heavily on our experience as pioneers of the earliest trials for modified T-cell therapies and gene therapies, as well as the strength of Penns research infrastructure, to make this study a reality.
Previous human trials using CRISPR technology have predominantly been conducted in China until several trials launched in the U.S. this year. The technology is currently being tested by researchers in Massachusetts to potentially treat genetic blood disorders like sickle cell disease and certain forms of inherited blindness. Penns team aims to test the approach on a total of 18 patients by the end of the trial.
More here:
Here Are the Early Results From the First US CRISPR Trial for Cancer - Philadelphia magazine
- Worldwide Markets for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing, Forecast to 2030 - Robust Pipeline of Therapy Candidates and... - December 2nd, 2019
- Pfizer and Novartis lead pharma spending spree on gene therapy - Gulf Today - December 2nd, 2019
- Korean biotech's shares soar for a 'best of ESMO' award it never received - Endpoints News - December 2nd, 2019
- Insider account of UCB's $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy and $120M windfall for execs - Endpoints News - December 2nd, 2019
- Global Gene Therapy for Age-related Macular Degeneration Market 2019 Development Status RetroSense Therapeutics, REGENXBIO, AGTC - Mach Tribune - December 2nd, 2019
- Harvard, MIT, teaching hospitals, industry partners pool resources to create a central facility for developing regenerative therapies - India... - December 2nd, 2019
- French-Swedish research team improves safety of DMD gene therapy - European Biotechnology - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- Partnership aims to accelerate cell and gene therapy - Harvard Gazette - November 28th, 2019
- Experts Barry Byrne, Jerry Mendell Lead NORD Webinar on Gene Therapy - SMA News Today - November 28th, 2019
- Pfizer, Novartis lead $2 billion spending spree on gene therapy production - Reuters - November 28th, 2019
- Global Gene Therapy Research Report 2019: Market Analysis, Trends, and Forecasts to 2025 - PRNewswire - November 28th, 2019
- UMass Med School gene therapy shows promising early results in tackling Tay-Sachs - Worcester Telegram - November 28th, 2019
- Sheffield research receives 800k to develop new gene therapy to treat CVD - News-Medical.net - November 28th, 2019
- Pfizer and Novartis lead $2bn spending on gene therapy production - Manufacturing Global - November 28th, 2019
- Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy | More News | News Channels - PipelineReview.com - November 28th, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community - November 28th, 2019
- 'Breakthrough' bladder cancer drug spinout gets $570M to back launch of a new gene therapy in the US - Endpoints News - November 28th, 2019
- FDA approves 5 new costly drugs well ahead of PDUFA dates - Endpoints News - November 28th, 2019
- Gene Therapy and Antisense Drugs Market Growing Massively by 2019-2026 Major Players GenVec Inc., Avigen Inc., Genome Therapeutics Corp., Tekmira... - November 28th, 2019
- Feds add fraud charges to the multitude of accusations made against former MiMedx execs - Endpoints News - November 28th, 2019
- Cell and Gene Therapy Consumables Market Size, CAGR, Trends 2019: Industry Growth, Demand, Share, Analysis till 2027 - World Industry Reports - November 28th, 2019
- How AI is Changing the Way We Treat Diseases and Disabilities - Forbes - November 28th, 2019
- Intermountain to open new center for pediatric precision medicine - Healthcare IT News - November 28th, 2019
- Pfizer, Novartis lead pharma spending spree on gene therapy production - Reuters - November 28th, 2019
- Gene Therapy Market Expected to Grow with a CAGR of 16.92% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com - Business Wire - November 28th, 2019
- Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma - November 28th, 2019
- Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy - P&T Community - November 28th, 2019
- Blackstone to invest $400 million in gene therapy venture with Ferring - Reuters - November 28th, 2019
- CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions - PRNewswire - November 28th, 2019
- New partnership aims to explore, cultivate innovations in cell and gene therapy - News-Medical.net - November 28th, 2019
- BIDMC joins local universities, teaching hospitals and industry partners in creating new central facility for regenerative therapies - Newswise - November 28th, 2019
- 6 Things About Biopharma to Be Thankful For - BioSpace - November 28th, 2019
- For Hemophilia A, BioMarin Seeks Approval of Its Gene Therapy in Europe - Hemophilia News Today - November 28th, 2019
- Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS - Endpoints News - November 28th, 2019
- There's one endpoint that the booming biopharma industry has failed at miserably: financial toxicity - Endpoints News - November 28th, 2019
- Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals - Endpoints News - November 28th, 2019
- Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test - Endpoints News - November 28th, 2019
- Global Cancer Gene Therapy Market Report with Study of North America, Europe and Asia-Pacific, South America, Middle East and Africa Regions -... - November 28th, 2019
- Make that 2 new sickle cell disease blockbuster hopefuls OK'd by the FDA in just a few days - Endpoints News - November 28th, 2019
- How will Gene Therapy continue to evolve in the next 10 years? - Montana Ledger - November 28th, 2019
- Global Gene Therapy for Age-related Macular Degeneration Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue... - November 28th, 2019
- Axovant Gene Therapies Ltd (NASDAQ:AXGT) Expected to Post Earnings of -$0.63 Per Share - Mitchell Messenger - November 24th, 2019
- $6 Million Expansion For Gene Therapy Facility Completed At Alachua's Progress Park - WUFT - November 23rd, 2019
- Worldwide Cell & Gene Therapy Market Insights Study, 2019-2024 - Market Set to Surpass a CAGR of 24%, Driven by Favorable Regulatory Support & Special... - November 23rd, 2019
- Govt to fund gene therapy research on NCDs, rare diseases - CNBCTV18 - November 23rd, 2019
- Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder - Yahoo Finance - November 23rd, 2019
- Breakthrough Gene Therapy Clinical Trial is the World's First That Aims to Reverse 20 Years of Aging in Humans - PRNewswire - November 23rd, 2019
- Fujifilm to invest $120M in gene therapy, build center in Texas - BioPharma Dive - November 23rd, 2019
- 1.2m investment in Stevenage Bioscience Catalyst for world-class cell and gene therapy - Pharmafield - November 23rd, 2019
- Gene therapy to reverse age by 20 years: World's first trial - Specialty Medical Dialogues - November 23rd, 2019
- Gene Therapy Industry Analysis by Growth, Competitive Strategies and Forecast Research Report 2019-2025 - Markets Gazette 24 - November 23rd, 2019
- Trio of gene therapies seeks to reverse age-related diseases to make us 'healthy, youthful later in life' - Genetic Literacy Project - November 23rd, 2019
- Royal recognition for neuroscience research at the University of Sheffield - India Education Diary - November 23rd, 2019
- University of Sheffield receives Queen's Anniversary Prize for innovation in neuroscience - News-Medical.net - November 23rd, 2019
- Comprehensive Study Reveals How Sandhoff Disease Treatment Market is Trending | Intrabio, Axovant Gene Therapies Ltd - VaporBlash - November 23rd, 2019
- Edited Transcript of CLSD earnings conference call or presentation 6-Nov-19 9:30pm GMT - Yahoo Finance - November 23rd, 2019
- New Gene Therapy Aims At Reversing Signs Of Aging - TheHealthMania - November 23rd, 2019
- Vertex invests in gene therapy manufacturing - BioPharma-Reporter.com - November 11th, 2019
- Year in Review: Ophthalmology - MedPage Today - November 11th, 2019
- Hemophilia Patients, Caregivers Identify Factors in Switching Treatments - Hemophilia News Today - November 11th, 2019
- A New Treatment Method May Cure Patients of Genetic Hearing Loss - PharmiWeb.com - November 11th, 2019
- Global Bleeding Disorders Therapeutics Market 2020-2024 | Evolving Opportunities with Baxter International Inc. & Bayer AG | Technavio - Business... - November 11th, 2019
- GOVX: Third Quarter 2019 Results and Update - Zacks Small Cap Research - November 11th, 2019
- Gene Therapy Market Trends, Technology and Forecast | by Top Companies Novartis AG, MeiraGTx Limited, Rocket Pharmaceuticals, Lonza, Biogen, Gilead... - November 11th, 2019
- Modified Protein Enhances the Accuracy of CRISPR Gene Therapy - DocWire News - November 11th, 2019
- Scientists are using gene therapy to treat a heart disease in dogs. Could humans be next? - 10News - November 11th, 2019
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for... - November 11th, 2019
- Gene Tech Company Claims to Have Found a Cure for HIV/AIDS - NewNowNext - November 11th, 2019
- 3 Cancer Treatment Stocks to Buy Right Now - The Motley Fool - November 11th, 2019
- How Gene Therapy Is Evolving to Tackle Complex... - Labiotech.eu - November 11th, 2019
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting - Business... - November 11th, 2019
- Edited Transcript of VYGR earnings conference call or presentation 6-Nov-19 1:00pm GMT - Yahoo Finance - November 11th, 2019
- Latest Trending Report Cancer Gene Therapy Market Trends and Business Growth with Industry Share, Revenue , Key Highlights and Opportunity 2025 - The... - November 11th, 2019
- The woman who should have got Alzheimers by 50, but didnt - The Irish Times - November 11th, 2019
- Edited Transcript of SRPT earnings conference call or presentation 7-Nov-19 9:30pm GMT - Yahoo Finance - November 11th, 2019
- Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -... - November 11th, 2019
- Insightful Growth of Cancer Gene Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Daily Watch Reports - November 11th, 2019
- Her daughter may die by age 10, but this mom keeps fighting to cure her rare disease - GMA - November 11th, 2019
- Edited Transcript of OTIC earnings conference call or presentation 5-Nov-19 9:30pm GMT - Yahoo Finance - November 11th, 2019